News & Presentations

Seattle, Wash., October 18, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Clay Siegall, Ph.D. as its Chairman of the Board of Directors.

Seattle, Wash., August 30, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the groundbreaking of its new development and manufacturing facility in Louisville, Colo. Construction of the state-of-the-art facility is a key milestone for the company and represents an important next step in bringing effective and accessible CAR T therapies to cancer patients.